First-of-its-Kind cell therapy trial targets devastating kidney disease
NCT ID NCT07423572
Summary
This is a small, early-stage study to test the safety and initial effectiveness of a new type of cell therapy called UCAR-T for people with a severe form of kidney disease that hasn't responded to other treatments. The therapy involves modifying a patient's own immune cells to potentially target and reduce the disease. The study will enroll 18 adults to see if this approach is safe and can help control the condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY IDIOPATHIC MEMBRANOUS NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Zhejiang Chinese Medical University
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.